US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
Editorial Director, Hematology/Oncology
Senior Managing Editor
This program is intended for physicians and other healthcare professionals who provide care for patients with lymphomas.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 17, 2016, through February 16, 2017:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Downloadable resource guide for patients who are receiving an FDA-approved BTK inhibitor, acalabrutinib or ibrutinib, from CCO.
Downloadable slides on treatment strategies for CLL including the most recent data on BTK inhibitors, BCL-2 inhibitor, PI3K inhibitors, and CAR T-cell therapy.
Enter characteristics of your patient with acute myeloid leukemia (AML) into this online tool to receive treatment recommendations from 5 experts
Results from a phase II trial of ibrutinib, lenalidomide, and rituximab in non-GCB DLBCL as reported by CCO from ASCO 2019
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.